Public Health Product Hops
Are there circumstances for which allowing a product hop resulted in a net benefit to society that exceeded the excess costs associated with the new product?

Are there circumstances for which allowing a product hop resulted in a net benefit to society that exceeded the excess costs associated with the new product?
Between the opioid crisis and the COVID-19 pandemic, America now suffers from a surplus of needless, untimely deaths.
Topics include off-label and compassionate drug use for COVID-19 and utilization and cost of naloxone for patients at high risk of opioid overdose.
By Scott Burris The rising public and legislative awareness of opioid overdose has been a case study in the twists and turns of culture, risk perception and the role of evidence in policy making. An interesting case study, which does not mean I understand what happened or why. I first got involved in overdose through…
By Scott Burris Phil Coffin and Sean Sullivan have published a cost-effectiveness study of interventions that equip heroin users and others to administer naloxone in the event of a witnessed opioid overdose. Naloxone is the standard antidote, and can easily be administered by lay people with a minimum amount of training. Family members and friends…